Engflag

Rexipra PLUS

Quick links to important sections

Rexipra PLUS

Rexipra PLUS_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rexipra PLUS

Quick Facts

Property Description
Active ingredients Escitalopram and Clonazepam
Form Tablet
Pharmacological class SSRI and Benzodiazepine (BZD)
Origin Synthetic psychotropic compounds
Route Oral administration

What Type of Medicine is Rexipra PLUS?

Rexipra PLUS is a prescription-only psychotropic medicine that is classified as a fixed-dose combination product for oral administration. It is fundamentally a combined antianxiety and antidepressant agent, a structure necessary due to its dual chemical composition. The medicine contains the SSRI (Selective Serotonin Reuptake Inhibitor) Escitalopram and the Benzodiazepine Clonazepam. Pharmacological studies have consistently supported the use of this dual-agent approach for managing complex emotional states, demonstrating a recognized pattern in clinical practice.

Composition: SSRI and Benzodiazepine Dual Classification

The medicine’s composition involves two components with fundamentally different mechanisms of action, both of which are synthetic compounds. Escitalopram is the active S-enantiomer that acts to influence Serotonin (5-HT) levels, contributing to mood stabilization. Clonazepam is classified as a CNS depressant that achieves a rapid calming effect by enhancing the inhibitory activity of Gamma-aminobutyric acid (GABA). The use of this fixed-dose tablet is often favored by healthcare professionals for promoting patient adherence to complex treatment regimens.

General Purpose of the Dual-Action Combination

The overarching purpose of this dual-agent formulation is to provide comprehensive support for emotional and mental equilibrium. The Benzodiazepine component is designed to deliver a rapid reduction of acute symptoms, such as severe nervous tension, complementing the SSRI component, which is intended to address the underlying chemical disposition through sustained Serotonin regulation. This strategy leverages the fast-onset relief of the BZD with the gradual, foundational mood improvement provided by the SSRI.

What side effects are possible with Rexipra PLUS?

Possible Side Effects and Safety Information

The official safety profile of Rexipra PLUS, a combination of Escitalopram (SSRI) and Clonazepam (Benzodiazepine), is structured by officially documented adverse reactions, their frequencies, and specific safety constraints. Key effects are often classified by System-Organ Class (SOC) in regulatory documents.

Commonly Documented Adverse Reactions

Side effects classified as Common (frequent) in regulatory labeling often affect the Nervous System and Gastrointestinal System. These include drowsiness, ataxia, insomnia, nausea, fatigue, and specific ejaculation disorders (ejaculatory delay). The Benzodiazepine component, Clonazepam, is associated with a high incidence of drowsiness and ataxia.

Serious Adverse Reactions and Warnings

Official labeling contains serious warnings, including a required Boxed Warning concerning the risk of Clinical Worsening and Suicidality in young adults, particularly during the initial few months of therapy or at times of dose changes. There is also a Boxed Warning for the risk of Physical Dependence and Withdrawal with continued Clonazepam use, and the potential for Profound Sedation and Respiratory Depression when used with opioids. Other documented risks include Serotonin Syndrome and reports of Abnormal Bleeding.

Population-Specific Safety Constraints

Safety notes are explicitly provided for specific patient populations. The medicine is contraindicated in individuals with significant liver disease and in those taking MAO Inhibitors. Caution is officially noted for use in older adults due to increased sensitivity to CNS depressant effects, and in patients with a history of QT interval prolongation (related to Escitalopram).

Overdose and Emergency Response

Overdose and when to seek help

This information is strictly derived from official government regulatory documents regarding the overdose profile of the combination of Escitalopram and Clonazepam.

Documented Overdose Manifestations

Overdosage with Rexipra PLUS may result in a range of symptoms derived from its two components. Documented manifestations include signs of central nervous system (CNS) toxicity, such as dizziness, tremor, confusion, stupor, and convulsions (seizures). Cardiovascular effects may present as changes in heart rhythm (arrhythmias) or decreased blood pressure (hypotension). Gastrointestinal effects, such as nausea and vomiting, and disturbances in electrolyte balance have also been observed.

Critical Overdose Risks

Overdose carries a risk of serious, life-threatening outcomes, including respiratory depression, coma, and fatal consequences. The risk of severe toxicity is explicitly increased by co-ingestion of other CNS depressants, including alcohol or opioids, and this scenario requires immediate critical care.

When Immediate Medical Help is Required

Emergency medical treatment must be sought without any delay for any suspected or known overdosage. If an excessive amount is taken by accident, immediate medical attention in a hospital or contact with a Poison Control Center (or equivalent emergency service) is required.

Emergency Management

Management is primarily supportive, focusing on general supportive measures such as airway management and monitoring of vital signs. A specific benzodiazepine antagonist, Flumazenil, may be considered for partial reversal of the sedative effects of the Clonazepam component; however, regulatory documents caution that its use in a mixed overdose (including with the SSRI component) may increase the risk of seizures.

Therapeutic Uses of Rexipra PLUS

What Rexipra PLUS Treats: Main Uses and Benefits

Therapeutic Scope

The combination formulation is commonly used to provide symptomatic support in complex emotional states, particularly when anxiety and depression occur together. This integrated approach is relevant in contexts involving heightened systemic burden, and is applied in addressing the symptoms that interfere with daily functioning, such as those associated with depressive and anxiety-related conditions. In clinical settings that involve acute or unstable symptom patterns, the combination is considered relevant for managing symptoms that interfere with daily comfort.

Symptom Management

This medication is commonly used when short-term symptomatic assistance is needed during episodes of sudden symptom escalation, helping to address symptoms related to heightened physiological activity, such as severe nervous tension. It also supports the long-term therapeutic management of chronic emotional disorders. The treatment contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Relief for Overlapping Symptoms

Symptom Domain General Benefit
Acute Nervous Tension Provides supportive relief when symptoms become temporarily overwhelming.
Chronic Worry & Low Mood Contributes to easing the overall symptom load over time.

Eligibility and Restrictions for Use

This section outlines the officially documented eligibility and non-eligibility profiles for Rexipra PLUS (a combination of escitalopram and clonazepam), strictly based on government regulatory information.

Populations that Must Not Use the Medicine (Contraindications)

Official labeling contraindicates use in patients with:

  • Hypersensitivity (allergy) to escitalopram, clonazepam, other benzodiazepines, or any inactive ingredient.
  • Concurrent use of Monoamine Oxidase Inhibitors (MAOIs), including non-selective, irreversible MAOIs, reversible MAO-A inhibitors (like moclobemide), or the non-selective reversible MAO-inhibitor linezolid.
  • Concurrent use of Pimozide (an antipsychotic medication).
  • Known QT interval prolongation or congenital long QT syndrome.
  • Significant liver disease or Acute Angle Glaucoma.

Restricted or Conditional Use

Certain groups require special consideration or a restricted status due to potential risks, as explicitly stated in regulatory warnings:

Population/Condition Eligibility Status Basis for Restriction
Pediatric Patients (Under 18) Not Established/Not Recommended Safety and effectiveness are not established; often excluded from routine use.
Pregnancy/Breastfeeding Not Recommended/Caution Components may pose risk to the fetus or infant; use is highly conditional.
Severe Renal Impairment Caution Risk of drug accumulation; requires close monitoring.
Unstable Epilepsy Not Recommended Risk of increasing seizure frequency.

Older adult patients (over 65) typically require caution and often a lower maximum dosage, reflecting altered drug metabolism.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This combination product carries risks associated with both its escitalopram and clonazepam components. Certain combinations are strictly contraindicated and must be avoided to prevent severe, life-threatening reactions.

Interaction Classification Example Agents/Categories Associated Risk/Mechanism
Contraindicated Monoamine Oxidase Inhibitors (MAOIs), Pimozide, Linezolid (IV), Methylene Blue (IV) Risk of Serotonin Syndrome, a potentially fatal condition involving altered mental status, autonomic instability, and neuromuscular changes. MAOIs must not be taken within 14 days of this medication.
Use with Caution Other Serotonergic Drugs (e.g., Triptans, Fentanyl, Tramadol, Tricyclic Antidepressants, St. John's Wort) Increased risk for Serotonin Syndrome due to cumulative serotonergic effects.
Agents Affecting Hemostasis (e.g., Warfarin, NSAIDs, Aspirin) Increased risk of Abnormal Bleeding (e.g., gastrointestinal hemorrhage, ecchymosis) due to the escitalopram component's effects on platelet function.
CNS Depressants (e.g., Alcohol, Opioids, Sedatives, other Anti-Anxiety Agents) Increased risk of additive CNS depression, leading to enhanced drowsiness, dizziness, and impaired motor performance from the clonazepam component.
Drugs Affecting CYP Enzymes (e.g., Carbamazepine, Cimetidine, Rifampicin) Potential for altered blood levels of this medication's components, which can decrease therapeutic effect or increase toxicity.
QT-Prolonging Drugs (e.g., Antiarrhythmics, certain Antipsychotics) Increased risk of serious heart rhythm abnormalities (e.g., QT prolongation, Torsade de Pointes).

It is essential to consult a healthcare professional regarding all co-administered medications, including non-prescription drugs and herbal supplements, before starting or stopping treatment.

Mechanism of Action

How Rexipra PLUS Works — Mechanism of Action

Dual-Pathway Neurotransmitter Regulation

The function of Rexipra PLUS is based on a dual pattern of neurotransmitter modulation across two distinct central pathways: the long-term modulation of the Serotonergic System and the immediate enhancement of the GABAergic System. This dual approach engages both pathways involved in neural homeostasis and the primary inhibitory system controlling neural excitability, resulting in changes across two primary neurotransmitter systems.

Inhibiting Serotonin Reuptake for Foundational Modulation

The escitalopram component acts as a selective inhibitor of the Serotonin Transporter (SERT), blocking the reabsorption of serotonin (5-HT) into the presynaptic neuron. This action increases the concentration of 5-HT in the synaptic cleft, driving long-term neuroadaptive changes that adjust activity within neural circuits governing emotional homeostasis and modulate emotional processing and response pathways over several weeks.

Potentiating GABA Signaling for Rapid Inhibition

The clonazepam component is a positive allosteric modulator of the GABA A receptor, which enhances the effects of the brain’s main inhibitory neurotransmitter, GABA. This mechanism rapidly increases chloride ion influx, leading to widespread neuronal hyperpolarization and a prompt dampening of central nervous system (CNS) excitability, producing changes consistent with sedation and decreased muscle tone.

Dosage and Administration Information

How to use Rexipra PLUS

The official usage of Rexipra PLUS, a fixed-dose tablet containing Escitalopram and Clonazepam, is governed by structured administration guidelines designed to address initial and long-term treatment needs.

Administration and Dosage Guidelines

Feature Official Regulatory Guideline
Route of Administration The medicine must be taken orally as a tablet.
Frequency Administration is typically once daily, and may be taken in the morning or evening.
Standard Adult Dose The initial dose for the Escitalopram component is typically 10 mg once daily. The maximum recommended daily dose for the Escitalopram component is 20 mg.
Dose Titration If an adult dose increase is necessary, it is officially recommended to occur only after a minimum of one week of treatment.
Intake Condition The tablet may be taken with or without food.

Official Procedural Steps

Initial Use and Treatment Duration

Rexipra PLUS is often employed for an initial treatment phase to achieve symptom stabilization. The regulatory standard of practice for combination products is often to subsequently transition to Escitalopram monotherapy for continued therapeutic management.

Population-Specific Adjustments

The recommended maximum dose for the Escitalopram component is 10 mg once daily for older adults and patients with hepatic (liver) impairment. Use of the medicine requires caution in patients with severe renal (kidney) impairment.

Discontinuation Protocol

Treatment must not be stopped abruptly. Official guidance strongly recommends a gradual dose reduction (tapering) when discontinuing the medicine to minimize the risk of discontinuation effects. The long-term usefulness of the medicine, especially the Escitalopram component, should be periodically re-evaluated by a healthcare professional.

Recent Clinical Evidence

Research evidence / Overview of studies for Rexipra PLUS

Evidence for Use in Managing Depression with Anxious Features

Research has been conducted exploring the combination of Escitalopram and Clonazepam for individuals diagnosed with Major Depression who also present with anxiety symptoms. Studies explored short-term symptom changes, typically over defined time intervals of 6 to 8 weeks, in conditions marked by functional limitations. These trials monitored changes using standardized scales that measure the intensity of depression and anxiety symptoms.

Studies observed patterns related to the time required for changes in depressive symptoms to become measurable in the combination group. However, when examining final symptom severity scores at the end of the short study period, reported measurements were often highly variable across the different research settings. The evidence contributes to understanding symptom patterns, particularly related to changes in early symptom activity, but the data show patterns related to using the combination strategy for addressing acute symptom burden.

Evidence for Use in Panic Disorder and Acute Anxiety

The combination was studied for outcomes capturing phases of heightened symptom activity, such as in individuals with Panic Disorder. Research explored short-term symptom changes and outcomes related to systemic or functional imbalance over defined time intervals, usually 4 to 8 weeks, monitoring measures like the frequency of reported acute episodes and overall anxiety levels. Studies also explored the body’s processing of the medication, including pharmacokinetic assessments, in healthy adult subjects.

Studies explored outcomes related to episodic or acute changes. Some findings described patterns where changes in measurements of acute anxiety and panic attack frequency evolved in the initial weeks of the study period. Pharmacokinetic findings indicate that the amount of Escitalopram and Clonazepam available in the body after taking the fixed-dose tablet was generally similar to the levels measured when the two active ingredients were taken separately.

Research on Long-Term Outcomes and Follow-Up

Research has primarily explored the use of this combination during acute episodes where symptoms become more noticeable. Information about the duration of any observed symptom evolution and the longer-term course for individuals using the fixed-dose combination remains insufficient, and certainty remains low. The long-term effects of using this specific combination are not fully established.

Study Quality, Limitations, and Evidence Gaps

Research provides context but not individual predictions; findings describe group patterns, not personal outcomes. Comparative evidence is limited specifically for the fixed-dose tablet versus separate prescriptions of the two components. Data for certain groups, such as older adults, adolescents, or those with other complex medical conditions, is limited. The overall findings help contextualize what has been observed so far but highlight that a full understanding of the long-term effects is not fully established, and more research is ongoing.

Key Studies & References

  1. Overview of efficacy and safety of escitalopram in major depressive disorder: a review of the literature
  2. NICE Guideline: Depression in adults: recognition and management

Frequently Asked Questions (FAQ)

Common questions about Rexipra PLUS (FAQ)

Q: Is Rexipra PLUS a habit-forming drug?

According to the official product information, the active ingredients in Rexipra PLUS are not generally classified as having a high risk of dependence. Regulatory documents state that when this medicine is used as prescribed by a healthcare provider, the risk of developing a substance use disorder is considered low.

Q: What is the main purpose of Rexipra PLUS?

Rexipra PLUS is officially indicated for treating specific mental health conditions. Studies and official information indicate that its authorized use is for the management of generalized anxiety disorder (GAD) and major depressive disorder (MDD). The medication is designed to address certain chemical imbalances in the brain associated with these conditions.

Q: Can I stop taking Rexipra PLUS abruptly?

Abruptly stopping this medication is not recommended according to regulatory documents. Official product information states that sudden discontinuation may lead to withdrawal-like symptoms. For this reason, official guidance suggests that gradual reduction may be required if the medication is to be stopped.

Q: How long until Rexipra PLUS starts working?

Clinical trial data suggest that noticeable improvements in symptoms may take several weeks. Clinical data often suggests that some patients may begin to notice a difference within two to four weeks of starting treatment. Achieving the full therapeutic benefit of Rexipra PLUS may take a longer period.

Q: Can I drink alcohol while on Rexipra PLUS?

Official product information and drug interaction warnings indicate that consuming alcohol while taking Rexipra PLUS may not be recommended. Alcohol may increase certain central nervous system (CNS) effects of the medicine. This interaction could potentially lead to effects such as increased drowsiness or impaired judgment.

Q: Does Rexipra PLUS cause sexual side effects?

Official product information notes that changes in sexual function are among the possible side effects associated with Rexipra PLUS. These side effects, which may include changes in desire or performance, are listed in the adverse reaction section of the regulatory documents. For detailed information, users are encouraged to refer to the full list in the dedicated section on side effects.

Q: What should I do if I miss a dose?

Official instructions typically suggest that if a dose is missed, it should be taken as soon as it is remembered. However, if it is near the time for the next scheduled dose, official guidance usually indicates that the missed dose should be skipped. The patient information emphasizes the importance of not taking two doses simultaneously.

Q: Is Rexipra PLUS safe for children?

The official product labeling indicates that the safety and effectiveness of Rexipra PLUS have not been established in individuals under 18 years of age. Therefore, according to regulatory sources, this medicine is not currently approved for use in pediatric patients.

How should Rexipra PLUS be stored and disposed of?

How to Store and Dispose of Rexipra PLUS?

Rexipra PLUS must be stored according to official regulatory conditions to maintain its stability and effectiveness.

Required Storage Conditions

Condition Requirement Statement
Temperature Store at controlled room temperature, specifically 25^circC (77^circF), with permitted excursions up to 30^circC.
Protection Keep the medicine out of reach of children and pets. Protect the tablets from moisture, excessive heat, and direct light.
Container Keep the product in its original container and ensure the container is tightly closed to prevent environmental degradation.

Official Disposal Instructions

Expired or unused tablets should be disposed of promptly using a drug take-back program or an authorized collection site. If a program is unavailable, follow the specific procedure for household trash disposal (mixing with an undesirable substance like dirt or used coffee grounds, then sealing in a bag). The product must not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Rexipra PLUS found in:

A-Z Index: